NanoViricides Inc. (NNVC)

[JG36]

The "exceptionalism" we object to is not the assumption that nanoviricides will prove to be exceptionally effective and flexible anti-virals. Indeed, we all hope they will.

The "exceptionalism" we object to is the assumption that all the rules of drug development that apply to other companies, including the costs and times involved, the amount of testing required, and regulatory hurdles that must be overcome, somehow don't apply to NNVC.